PCMT1

Across TCGA pan-cancer cohorts, PCMT1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PCMT1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PCMT1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PCMT1 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and LUAD are the cancer types where PCMT1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCMT1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	−0.617	<.001	11	view →
COAD	Male	III,IV	−0.769	<.001	10	view →
LUAD	Female	III,IV	−0.623	<.001	9	view →
LSCC	Male	III,IV	−0.548	<.001	9	view →
CCRCC	Female	All	+0.184	<.001	8	view →
PDAC	Female	II,III,IV	−0.396	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PCMT1–HNSC

Open the HNSC breakdown →